Roche

Roche operates through two main business divisions: Pharmaceuticals and Diagnostics, creating a unique integrated healthcare company that combines treatment and diagnostic capabilities. This dual focus enables Roche to deliver personalized healthcare solutions, matching patients with the most effective treatments based on diagnostic information and molecular characteristics.

The Pharmaceuticals division develops and manufactures prescription medicines across multiple therapeutic areas, with particular strength in oncology, immunology, neuroscience, infectious diseases, and rare diseases. Roche's pharmaceutical portfolio includes both established blockbuster products and innovative new treatments that address significant unmet medical needs. The division maintains a global research and development network with facilities across multiple continents, investing billions annually in pharmaceutical innovation, clinical trials, and regulatory approvals.

The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices that support healthcare professionals in disease detection, monitoring, and treatment selection. Roche's diagnostic capabilities include automated laboratory systems, molecular testing platforms, and digital health solutions. The division's integrated approach with pharmaceuticals creates unique advantages in personalized medicine, enabling precise treatment selection based on diagnostic information.

Roche's business philosophy emphasizes innovation, patient-centricity, and sustainable value creation. The company maintains a strong focus on research and development, with approximately 20% of pharmaceutical revenues invested in R&D activities. This investment supports a robust pipeline of new treatments and diagnostic solutions, with 10 key molecules advancing into phase III development in 2025 alone.

Financial performance in 2025 demonstrated the strength of Roche's integrated business model. The company reported 7% sales growth at constant exchange rates to CHF 61.5 billion, with the Pharmaceuticals Division achieving 9% growth and the Diagnostics Division growing 2%. Core operating profit increased by 13%, reflecting operational efficiency and strong demand for both pharmaceutical and diagnostic solutions.

Key growth drivers in 2025 included Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. These products demonstrate Roche's strength across multiple therapeutic areas and its ability to deliver innovative treatments that address significant patient needs.

Looking toward 2026, Roche expects Group sales growth in the mid single digit range and core earnings per share growth in the high single digit range at constant exchange rates. The company plans to further increase its dividend to CHF 9.80 per share, which would mark the 39th consecutive dividend increase if approved by shareholders. For 2026, Roche is shifting focus from consolidation to optimization, emphasizing internal pipeline development and R&D process improvements to enhance productivity and decision-making.

Roche's strategic priorities include investing in programs with potential to redefine care standards, particularly in oncology, neuroscience, and immunology. The company maintains a $10 billion annual budget for potential acquisitions and partnerships, prioritizing strategic fit and scientific differentiation over transaction size. This approach reflects Roche's commitment to long-term value creation and sustainable growth while maintaining operational discipline.

Roche was founded in 1896 by Fritz Hoffmann-Oeri in Basel, Switzerland, establishing the company as "F. Hoffmann-La Roche & Co." The founder's vision was to create innovative pharmaceutical solutions that would serve patients globally, building on the emerging field of industrial pharmaceutical manufacturing. Fritz Hoffmann-Oeri's approach combined scientific rigor with business acumen, establishing principles that continue to guide the company today.

Throughout the early 20th century, Roche expanded its product portfolio and became known for its commitment to pharmaceutical innovation and quality. The company established itself as one of Switzerland's leading pharmaceutical manufacturers, with products serving diverse therapeutic areas including vitamins, hormones, and antibiotics. Roche became a trusted brand among healthcare professionals and patients, building a reputation for reliability and scientific excellence.

The mid-20th century marked significant expansion for Roche, particularly through strategic acquisitions and international growth. In 1964, Roche acquired a majority stake in Genentech, establishing a foundation for future biotechnology leadership. The company expanded into diagnostics, becoming a leader in laboratory testing and diagnostic solutions through acquisitions like Boehringer Mannheim in 1997. Roche established itself as a leader in oncology, immunology, and infectious diseases through both internal development and strategic acquisitions.

The 1990s and early 2000s represented a period of transformation for Roche, with major investments in biotechnology and personalized medicine. The company strengthened its position in oncology with breakthrough treatments like Herceptin (trastuzumab) for breast cancer and Rituxan (rituximab) for non-Hodgkin lymphoma. These innovations established Roche as a leader in targeted cancer therapies and personalized medicine approaches.

In recent decades, Roche has continued to focus on innovation in pharmaceuticals and diagnostics, investing heavily in molecular diagnostics, precision medicine, and digital health solutions. The company has maintained its leadership position in oncology while expanding into neuroscience, immunology, and rare diseases. Roche's integrated approach combining pharmaceuticals and diagnostics has created unique capabilities in personalized healthcare.

The year 2025 marked another strong performance year for Roche, with the company reporting 7% sales growth at constant exchange rates to CHF 61.5 billion. The Pharmaceuticals Division achieved 9% growth, driven by strong performance of key products including Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. The Diagnostics Division grew 2%, demonstrating resilience despite healthcare pricing reforms in China.

Roche's 2025 achievements included significant regulatory approvals and clinical development milestones. The company received US and EU approval for the subcutaneous form of Lunsumio for blood cancer and EU approval for Gazyva/Gazyvaro for lupus nephritis. Roche advanced 10 key molecules into phase III development and received EU CE marks for innovative diagnostic tests including the Elecsys Dengue Ag test and cobas BV/CV assay. These achievements demonstrate Roche's continued commitment to innovation and its ability to deliver new treatments and diagnostic solutions to patients worldwide.

Roche has committed to achieving net zero carbon emissions by 2045 and has set near-term and long-term targets validated by the Science Based Targets initiative in 2025. The company's climate strategy includes reducing absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030 against a 2019 baseline. In 2024, Roche reduced Scope 1 and 2 emissions by approximately 40% against the 2019 baseline, ahead of its 2025 interim target.

The company has committed to increasing sustainable electricity to 100% by 2025 and has made substantial progress toward this goal. Roche sources renewable electricity for a significant portion of its global manufacturing operations and has invested in energy efficiency programs across production facilities. The company participates in the Energize programme, which aims to increase access to renewable energy electricity for suppliers to the pharmaceutical industry.

Roche is a founding member of the Biopharma Sustainability Roundtable (established 2013) and has been a member of the World Business Council for Sustainable Development since 1995, participating actively in Circular Plastics & Packaging and Partnership for Carbon Transparency projects. The company joined the Sustainable Markets Initiative in 2021 as a founding member and actively participates in the Health Systems Industry Taskforce.

The company has set targets to halve the environmental impact of its operations and products from a 2019 baseline by 2029. Water consumption reduction targets include a 15% decrease by 2025 from a 2020 baseline, with nutrient discharge reductions of 5% for nitrogen and 90% for phosphorus. Waste management goals include reducing general waste by 10% and achieving an 80% recycling rate for general waste by 2025.

Roche is not a Certified B Corporation, and the company does not hold cruelty-free certification from Leaping Bunny or PETA at the group level, as pharmaceutical companies are required to conduct animal testing for regulatory approval in most jurisdictions. The company states it is pioneering and promoting innovative approaches in preclinical research to replace animal testing where scientifically and ethically appropriate.

In 2025, Roche received a Silver medal from EcoVadis sustainability rating agency, achieving a score of 69 out of 100, placing the company in the top 15% of companies rated. In 2024, Roche ranked 11th out of 20 of the world's biggest pharmaceutical companies assessed by the Access to Medicine Index.

Roche publishes an annual Sustainability Report with independently assured performance data and maintains extensive ESG disclosure through its investor relations materials. The company's sustainability governance is integrated into its business strategy, with commitment from senior management reflected in the sustainability governance structure.

Roche has received consistent recognition for innovation, research capability, and workplace practices from independent rating organizations and industry bodies.

In 2026, Roche and its subsidiary Genentech were both recognized on Glassdoor's Best Places to Work list in the United States, reflecting employee satisfaction and workplace culture. The company was named one of the world's top 10 BioPharma employers in the Science Magazine 2025 list, demonstrating its reputation as an employer of choice in the life sciences sector.

Roche has been included in Fortune's World's Most Admired Companies ranking, reflecting peer and analyst respect for the company's operational capabilities and market position. The company maintains a presence in major ESG indices, including the Dow Jones Sustainability Index North America, assessed annually by S&P Global for ESG performance among large cap companies.

The company's innovation capabilities have been recognized through its consistent inclusion in pharmaceutical industry innovation rankings. Roche's R&D productivity, measured by the number of new molecular entities in development and regulatory approvals achieved, places it among the most innovative pharmaceutical companies globally.

Roche's 39 consecutive years of dividend increases, pending shareholder approval for 2026, demonstrates financial stability and commitment to shareholder returns. This track record places Roche among a select group of companies with multi-decade dividend growth histories.

Roche has faced regulatory and legal challenges typical of large pharmaceutical companies operating in highly regulated markets globally.

In October 2025, Roche suffered a setback when India's Supreme Court allowed generic versions of Evrysdi (risdiplam) for spinal muscular atrophy to be manufactured and sold in India. The court's decision provided an important victory to patient advocates who argue drug makers tweak patents to extend exclusivity. This ruling reflects ongoing tensions between pharmaceutical intellectual property protection and access to medicines in emerging markets.

In March 2026, Russia's Biocad faced potential market loss for cancer drug pertuzumab due to a dispute with Roche over biosimilar development and patent rights. The dispute highlights the complex intellectual property landscape surrounding biologic medicines and biosimilar competition.

Roche has been involved in industry disputes with competitors. In a notable case, Bayer was found to have discredited the pharmaceutical industry after a dispute with Roche, with Bayer claiming that Roche made false and disparaging allegations of deliberate document falsification during business negotiations. The case was adjudicated by industry regulatory bodies.

Like other major pharmaceutical companies, Roche faces ongoing scrutiny regarding drug pricing, particularly in the United States and Europe. The company's pricing strategies for oncology and rare disease treatments have been subject to public debate and regulatory review, though no major pricing-related fines or settlements have been reported in recent years.

Roche's diagnostics business has faced challenges related to healthcare pricing reforms in China, which impacted the division's 2025 performance with a 12% sales decrease in the Asia-Pacific region. These reforms reflect broader government efforts to control healthcare costs and improve access to diagnostic services.

The company maintains transparency regarding legal proceedings through its annual Finance Report, which provides an overview of significant legal cases. As of the 2025 Finance Report, no material litigation beyond ordinary course business disputes was disclosed.